Publication Name	World Journal of Neurology
Manuscript ID	15133
Country	United States

Received	2014-11-11 10:20
Peer-Review Started	2014-11-11 16:15
First Decision by Editorial Office Director
Return for Revision	2014-12-30 16:52
Revised	2015-01-12 06:25
Publication Fee Transferred
Second Decision by Editor	2015-01-28 11:50
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-02-09 10:14
Articles in Press	2015-02-09 10:14
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-26 19:11
Publish the Manuscript Online	2015-03-31 10:53

ISSN	2218-6212 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Neurosciences
Manuscript Type	Minireviews
Article Title	Rituximab in neuromyelitis optica: A review of literature
Manuscript Source	Invited Manuscript
All Author List	Ericka Wong, Vijay A Vishwanath and Ilya Kister
Funding Agency and Grant Number	Funding Agency Grant Number National Multiple Sclerosis Society (NMSS) Guthy-Jackson Charitable Foundation
Corresponding Author	Dr. Ilya Kister, MD, Department of Neurology, NYU Multiple Sclerosis Care Center, 240 E 38th St, New York, NY 10026, United States. ilya.kister@nyumc.org
Key Words	Neuromyelitis optica; Rituximab; Longitudinally extensive transverse myelitis; Optic neuritis; CD19+; CD27+
Core Tip	Relapsing neuromyelitis optica (NMO) is an autoimmune disorder of the central nervous system that often results in severe disability and death if untreated. Rituximab, an anti-CD20 monoclonal antibody, appears to be a promising treatment option for NMO. In this review, we summarize the results of 13 observational studies that assessed efficacy of Rituximab in neuromyelitis optica. On average, 66% of patients remained relapse-free during treatment period and in the majority of patients disability scores have stabilized or improved. Monitoring response to rituximab with CD19+ and CD 27+ cell counts appears to improve outcomes.
Publish Date	2015-03-31 10:53
Citation	Wong E, Vishwanath VA, Kister I. Rituximab in neuromyelitis optica: A review of literature. World J Neurol 2015; 5(1): 39-46
URL	http://www.wjgnet.com/2218-6212/full/v5/i1/39.htm
DOI	http://dx.doi.org/10.5316/wjn.v5.i1.39

Full Article (PDF)	WJN-5-39.pdf
Full Article (Word)	WJN-5-39.doc
Manuscript File	15133-Review.docx
Answering Reviewers	15133-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15133-Conflict-of-interest statement.pdf
Copyright License Agreement	15133-Copyright assignment.pdf
Peer-review Report	15133-Peer-review(s).pdf
Scientific Misconduct Check	15133-Scientific misconduct check.pdf
Scientific Editor Work List	15133-Scientific editor work list.pdf